Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026)
Sunshine Biopharma (SBFM) posted Return on Capital Employed of 27.36% for Q1 2026, down 6.93% on a QoQ basis from 25.58% in Q4 2025, and down 368.0% year-over-year from 10.21% in Q1 2025.
Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2026) Analysis & Trends
Sunshine Biopharma's Return on Capital Employed history runs 11 years deep, the most recent figure standing at 27.36% for Q1 2026.
- Quarterly Return on Capital Employed fell 368.0% year-over-year to 27.36% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.36% (down 368.0% YoY) and the FY2025 annual result came in at 26.08%, down 41.0% from the prior year.
- Return on Capital Employed was 27.36% for Q1 2026 at Sunshine Biopharma, down from 25.58% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 9.57% in Q3 2022 and bottomed at 130.15% in Q1 2023.
- A 5-year average of 43.88% and a median of 25.58% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 27810 bps — and 2023, when it tumbled 11143 bps.
- Sunshine Biopharma's Return on Capital Employed stood at 96.01% in 2022, then jumped by 77 bps to 21.91% in 2023, then slipped by 10 bps to 24.02% in 2024, then declined by 7 bps to 25.58% in 2025, then fell by 7 bps to 27.36% in 2026.
- Business Quant data shows SBFM's Return on Capital Employed at 27.36% in Q1 2026, 25.58% in Q4 2025, and 25.82% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 92.29 Bn | 90.43 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 33.09 Bn | 31.15 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 27.76 Bn | 23.70 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 22.94 Bn | 20.79 Bn | 648.10 Mn | 21.43% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.51 Bn | 18.70 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 18.16 Bn | 16.84 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.84 Bn | 12.41 Bn | 785.00 Mn | 5.24% |
| 10 | Sunshine Biopharma | 696,643.46 | -6.22 Mn | 2.18 Mn | -27.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.36% |
| Dec 31, 2025 | -25.58% |
| Sep 30, 2025 | -25.82% |
| Jun 30, 2025 | -25.98% |
| Mar 31, 2025 | -23.67% |
| Dec 31, 2024 | -24.02% |
| Sep 30, 2024 | -19.53% |
| Jun 30, 2024 | -18.12% |
| Mar 31, 2024 | -18.76% |
| Dec 31, 2023 | -21.91% |
| Sep 30, 2023 | -117.63% |
| Jun 30, 2023 | -121.20% |
| Mar 31, 2023 | -130.15% |
| Dec 31, 2022 | -96.01% |
| Sep 30, 2022 | -9.57% |
| Jun 30, 2022 | -9.77% |
| Mar 31, 2022 | -30.97% |
| Dec 31, 2021 | -107.91% |
| Sep 30, 2021 | -148.34% |
| Jun 30, 2021 | -172.59% |